Dyne Therapeutics, Inc. DYN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -58.9%+5.1pp | -55.7%+32.3pp | -60.7%+8.0pp | -61.3%-8.9pp | -64%+7.5pp | |
| Return on assets | -50.2%+8.9pp | -47.5%+26.6pp | -51.8%+8.7pp | -53.1%-5.3pp | -59.1%+4.4pp | |
| Return on invested capital | -188.2%-12.8pp | -200.8%— | -205.6%+47.7pp | -220.3%-12.6pp | -175.4%-10.9pp | |
| Liquidity | ||||||
| Current ratio | 19.9×-0.4× | 22.3×+6.7× | 13.5×-3.6× | 16.8×-9.8× | 20.4×-1.5× | |
| Quick ratio | 19.9×-0.4× | 22.3×+6.7× | 13.5×-3.6× | 16.8×-9.8× | 20.4×-1.5× | |
| Cash ratio | 14.7×+0.8× | 17.6×+7.3× | 9.6×-2.7× | 11.7×-8.7× | 13.9×+1.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.2× | 0.2×+0.1× | 0.2×+0.1× | 0.2×+0.2× | 0×0.0× | |
| Debt-to-assets | 0.2×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.2×+0.1× | 0×0.0× | |
| Interest coverage | -45.3×— | -75.6×— | -149.8×— | -4,689.8×— | —— | |
| Valuation | ||||||
| Market capitalization | $2.99B+153% | $3.22B+34.3% | $1.8B-45.8% | $1.21B-63.0% | $1.18B-48.6% | |
| Enterprise value | $2.41B+228% | $2.5B+25.7% | $1.35B-52.2% | $844.31M-68.5% | $734.32M-64.3% | |
| Price / book | 3.5×+1.7× | 3.3×-0.5× | 2.6×-2.1× | 2.1×-2.1× | 1.8×-3.0× | |
| Free cash flow yield | -14.8%+12.5pp | -12.6%-0.3pp | -21%-13.7pp | -30%-23.2pp | -27.3%-17.7pp | |
| Earnings yield | -15.1%+15.9pp | -13.9%-0.6pp | -23.5%-14.7pp | -34.2%-26.3pp | -31%-19.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Dyne Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Dyne Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.